Study

Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. – Cost Effective Supplements

Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.

Quick navigation


http://www.ncbi.nlm.nih.gov/pubmed/30705687


Conclusion of this study

NC supplementation in overweight/obese NAFLD patients improved glucose indices, lipids, inflammation, WC, nesfatin, liver transaminases, and fatty liver degree. Accordingly, the proposed mechanism for ameliorating NAFLD with NC was approved by the increased serum nesfatin and likely consequent improvements in inflammation, lipids, and glucose profile. Further trials of nano-curcumin's effects are suggested.


Supplements analyzed in this study

Curcumin

Health conditions analyzed in this study

No health conditions information for this study.

Functions related to this study

Detox


Slightly Positive
Curcumin

Heart health


Slightly Positive
Curcumin

Immunity


Slightly Negative
Curcumin

Insulin control


Slightly Positive
Curcumin


Body systems related to this study


Cardiovascular System

Digestive System

Endocrine System

Immune System
Scroll to top